KB Asset Management Bets on 'Medical AI'...Solidifies Position as JLK's Second-Largest Shareholder [fn Market Watch]

[Financial News]  KB Asset Management has purchased additional shares in JLK, a medical artificial intelligence (AI) company.
About three months after becoming a major shareholder with a stake of more than 5% in June, it raised its ownership to the mid-6% range. Although the investment is classified as passive, the institutional investor's decision to increase its stake again within a relatively short period has drawn attention.
According to the financial investment industry on the 6th, KB Asset Management's holdings in JLK increased by 376,819 shares, from 1,309,845 to 1,686,664. Its stake also rose by 1.47 percentage points, from 5.09% to 6.56%.
KB Asset Management first joined JLK's list of major shareholders in June after securing a 5.09% stake. It then made additional purchases, strengthening its position as the company's second-largest shareholder. Its stated investment purpose is 'passive investment,' rather than participation in management.
The market is focusing on the fact that JLK has moved beyond the regulatory approval stage and entered the actual commercialization phase in the United States and Japan. For medical AI companies, the factors determining corporate value are shifting from technology development and regulatory approvals to hospital adoption and the generation of revenue.
JLK has obtained Food and Drug Administration (FDA) approval for seven stroke AI solutions in the United States and is pursuing strategies for adoption by local medical institutions and insurance reimbursement. In Japan, it has also secured regulatory approval for seven brain-imaging AI solutions. The company has signed contracts with five local medical device distributors and is expanding its hospital supply network.
In particular, reimbursement and hospital adoption in the United States, along with the expansion of actual supply through local distribution networks in Japan, are considered key factors that will determine future earnings. The next stage of evaluation will depend not on the number of regulatory approvals, but on how effectively JLK can convert them into revenue.
A JLK official said, "We are accelerating the commercialization of our medical AI business and expanding into global markets, centered on the United States and Japan." The official added, "We will connect the regulatory approvals we have secured and our local business foundations to actual adoption by medical institutions and commercialization results."
An official in the financial investment industry noted, "It is noteworthy that an institutional investor made additional purchases within a relatively short period after securing a stake of more than 5%." The official added, "However, since the stated investment purpose is passive, the key to a rerating of the company's valuation will be how much hospital adoption and revenue actually follow in the United States and Japan, rather than the increase in its stake itself." 
[email protected] Reporter Kim Kyung-ah Reporter